RYFLECTA Trademark

Trademark Overview

On Friday, December 14, 2012, a trademark application was filed for RYFLECTA with the United States Patent and Trademark Office. The USPTO has given the RYFLECTA trademark a serial number of 85803004. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 8, 2016. This trademark is owned by Millennium Pharmaceuticals, Inc.. The RYFLECTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the prevention and treatment of cancer and of auto-immune and inflammation diseases
ryflecta

General Information

Serial Number85803004
Word MarkRYFLECTA
Filing DateFriday, December 14, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 8, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2013

Trademark Statements

Goods and ServicesPharmaceuticals for the prevention and treatment of cancer and of auto-immune and inflammation diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 2, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMillennium Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NameMillennium Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, August 8, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, August 8, 2016ABANDONMENT - NO USE STATEMENT FILED
Wednesday, November 25, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 24, 2015EXTENSION 5 GRANTED
Monday, November 23, 2015EXTENSION 5 FILED
Monday, November 23, 2015TEAS EXTENSION RECEIVED
Wednesday, July 8, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 7, 2015EXTENSION 4 GRANTED
Friday, June 19, 2015EXTENSION 4 FILED
Saturday, July 4, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, June 19, 2015TEAS EXTENSION RECEIVED
Friday, January 9, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 8, 2015EXTENSION 3 GRANTED
Tuesday, December 16, 2014EXTENSION 3 FILED
Tuesday, December 16, 2014TEAS EXTENSION RECEIVED
Friday, July 11, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 10, 2014EXTENSION 2 GRANTED
Thursday, June 12, 2014EXTENSION 2 FILED
Tuesday, July 8, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, June 12, 2014TEAS EXTENSION RECEIVED
Thursday, February 27, 2014CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Saturday, November 23, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 21, 2013EXTENSION 1 GRANTED
Thursday, November 21, 2013EXTENSION 1 FILED
Thursday, November 21, 2013TEAS EXTENSION RECEIVED
Thursday, November 21, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 2, 2013NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 7, 2013PUBLISHED FOR OPPOSITION
Wednesday, April 17, 2013NOTICE OF PUBLICATION
Wednesday, April 3, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, April 3, 2013ASSIGNED TO LIE
Saturday, March 30, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 30, 2013ASSIGNED TO EXAMINER
Wednesday, January 2, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, December 18, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

ryflecta immune inflammation diseases auto cancer prevention treatment pharmaceuticals